Over the past few years, investors have moved away from somewhat speculative and unprofitable companies to put their money ...

In this article, we are going to take a look at where Editas Medicine, Inc. (NASDAQ:EDIT) stands against the other biotech penny stocks. In 2024, the healthcare industry has been doing well ...

The small-cap biotech could run into funding problems ahead. Editas Medicine looks like a high-risk, high-reward play. Editas Medicine's most advanced candidate is EDIT-301, which targets sickle ...

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR ...

Editas Medicine is a clinical-stage drugmaker developing CRISPR-based gene therapies. So far, Editas Medicine's candidate for sickle cell disease patients is performing well in clinical trials.

Editas Medicine, Inc. focuses on gene-editing using CRISPR technology to develop medicines for previously untreatable or under-treated diseases. The company's leading product, EDIT-301 ...

A look at the shareholders of Editas Medicine, Inc. (NASDAQ:EDIT) can tell us which group is most powerful. The group holding the most number of shares in the company, around 71% to be precise ...

Editas Medicine presents preclinical data on gene editing at ASGCT, aiming to develop candidates for hematopoietic and liver therapies by 2025. Editas Medicine, Inc. announced its progress in the ...

You can reach Jason on Signal at JasonMast.05. Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for ...

Good morning, everyone, and thank you for joining Editas Medicine’s Strategic Update Webinar. This webinar is being recorded and can be accessed in the future through this same link or through ...